Favipiravir

Product Description

Favipiravir is a viral RNA polymerase inhibitor; exhibits no effects on mammalian RNA polymerase. Prodrug that is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5'-triphosphate (RTP). Reduces infection rate of SARS-CoV-2 in Vero E6 cells in vitro (IC₅₀ = 61.88 μM). Inhibits influenza virus RNA-dependent RNA polymerase (RdRP) activity (IC₅₀ = 341 nM). Induces lethal mutagenesis in MDCK cells inoculated with seasonal influenza A (H1N1) viruses. Protects mice against Ebola virus.

Solubility

Preparing Stock Solutions for Favipiravir

The following data is based on the product molecular weight 157.10

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	6.37 mL	31.83 mL	63.65 mL
5 mM	1.27 mL	6.37 mL	12.73 mL
10 mM	0.64 mL	3.18 mL	6.37 mL
50 mM	0.13 mL	0.64 mL	1.27 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Furuta In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob.Agents Chemother. 2002 PMID: 11897578
• Wang Remdesivir and Chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 PMID: 32020029